Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 or 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 31, 2024

Azenta, Inc.

(Exact name of registrant as specified in its charter)


Delaware	0-25434	04-3040660
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)


200 Summit Drive, Burlington, MA 01803
(Address of principal executive offices and Zip Code)

(978) 262-2400

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	AZTA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01Regulation FD Disclosure.

As previously announced, effective October 1, 2023, Azenta, Inc. (the “Company”) realigned its organizational structure to three principal business segments to enhance its commercial strategy for accelerating growth and to enable additional profitability initiatives. The Company’s operating and reportable segments effective in the first quarter of fiscal 2024 (which align with how the Company’s Chief Operating Decision Maker manages the business, allocates resources, and assesses performance) consist of the following:

●

Multiomics. The Multiomics business resources operate under a single business unit that provides genomic and other sample analysis services, including gene sequencing and gene synthesis.

●

Sample Management Solutions. Sample & Repository Solutions, Ultracold Systems, and Consumables and Instruments resources operate as a single business unit offering end-to-end sample management services and products.

●

B Medical Systems. B Medical Systems business resources operate as a single business unit focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations.

For informational purposes, included in Exhibit 99.1 to this report, and incorporated into this Item 7.01 by reference, is the Company’s historical recast of segment information that reflects the segment changes noted above for fiscal years 2023 and 2022 and the quarters therein.

Limitation on Incorporation by Reference. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.


Exhibit No.		Description
99.1		Supplemental Information – Historical Recast of Segment Information
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	AZENTA, INC.

	/s/ Jason W. Joseph
Date: January 31, 2024	Jason W. Joseph
	Senior Vice President, General Counsel and Secretary

Exhibit 99.1

Notes on Non-GAAP Financial Measures

Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, purchase price accounting adjustments, tariff adjustments, restructuring charges, rebranding and transformation costs, contingent consideration adjustments, and merger, acquisition, and costs related to share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.

Revenue from Continuing Operations – Fiscal 2023


	Quarter Ended								Year Ended
Dollars in millions	September 30,		June 30,		March 31,		December 31,		September 30,
Revenue from Continuing Operations	2023		2023		2023		2022		2023
Sample Management Solutions	$	82	$	75	$	71	$	75	$	304
Multiomics		61		64		62		61		248
B Medical Systems		29		27		15		42		113
Azenta Total	$	172	$	166	$	148	$	178	$	665

Revenue from Continuing Operations – Fiscal 2022


	Quarter Ended								Year Ended
Dollars in millions	September 30,		June 30,		March 31,		December 31,		September 30,
Revenue from Continuing Operations	2022		2022		2022		2021		2022
Sample Management Solutions	$	75	$	73	$	81	$	76	$	305
Multiomics		63		59		65		64		251
B Medical Systems		—		—		—		—		—
Azenta Total	$	138	$	133	$	146	$	140	$	555

Reconciliation of GAAP to Non-GAAP Gross Profit – Fiscal 2023


	Sample Management Solutions
	Quarter Ended																Year Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
Dollars in thousands	2023				2023				2023				2022				2023
GAAP gross profit	$	38,296	46.8	%	$	34,930	46.4	%	$	27,544	38.8	%	$	32,035	42.5	%	$	132,806	43.7	%
Adjustments:
Amortization of completed technology		867	1.1			744	1.0			933	1.3			429	0.6			2,973	1.0
Purchase accounting impact on inventory		—	—			—	—			—	—			—	—			—	—
Non-GAAP adjusted gross profit	$	39,163	47.9	%	$	35,674	47.3	%	$	28,477	40.1	%	$	32,465	43.0	%	$	135,779	44.7	%

	Multiomics
	Quarter Ended																Year Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
Dollars in thousands	2023				2023				2023				2022				2023
GAAP gross profit	$	26,808	43.9	%	$	28,294	44.3	%	$	27,003	43.4	%	$	27,716	45.4	%	$	109,820	44.2	%
Adjustments:
Amortization of completed technology		1,211	2.0			1,220	1.9			1,226	2.0			1,215	2.0			4,874	2.0
Purchase accounting impact on inventory		—	—			—	—			—	—			—	—			—	—
Non-GAAP adjusted gross profit	$	28,019	45.8	%	$	29,514	46.2	%	$	28,229	45.4	%	$	28,931	47.4	%	$	114,694	46.2	%

	B Medical Systems
	Quarter Ended																Year Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
Dollars in thousands	2023				2023				2023				2022				2023
GAAP gross profit	$	2,930	10.0	%	$	4,781	17.9	%	$	(1,311)	(8.7)	%	$	14,114	33.7	%	$	20,514	18.1	%
Adjustments:
Amortization of completed technology		2,691	9.1			2,692	10.1			2,742	18.1			2,523	6.0			10,647	9.4
Purchase accounting impact on inventory		927	3.1			2,956	11.0			2,912	19.3			2,868	6.9			9,664	8.5
Non-GAAP adjusted gross profit	$	6,548	22.3	%	$	10,428	39.0	%	$	4,343	28.7	%	$	19,506	46.6	%	$	40,824	36.1	%

	Azenta Total
	Quarter Ended																Year Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
Dollars in thousands	2023				2023				2023				2022				2023
GAAP gross profit	$	68,034	39.5	%	$	68,005	41.0	%	$	53,236	35.9	%	$	73,865	41.4	%	$	263,140	39.6	%
Adjustments:
Amortization of completed technology		4,769	2.8			4,656	2.8			4,901	3.3			4,168	2.3			18,494	2.8
Purchase accounting impact on inventory		927	0.5			2,956	1.8			2,912	2.0			2,869	1.6			9,664	1.4
Non-GAAP adjusted gross profit	$	73,730	42.8	%	$	75,617	45.6	%	$	61,049	41.1	%	$	80,902	45.4	%	$	291,298	43.8	%

Reconciliation of GAAP to Non-GAAP Gross Profit – Fiscal 2022


	Sample Management Solutions
	Quarter Ended																Year Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
Dollars in thousands	2022				2022				2022				2021				2022
GAAP gross profit	$	31,606	42.2	%	$	33,709	45.9	%	$	39,702	49.3	%	$	35,929	47.4	%	$	140,947	46.3	%
Adjustments:
Amortization of completed technology		528	0.7			378	0.5			394	0.5			330	0.4			1,631	0.5
Tariff adjustment		—	—			—	—			—	—			—	—			—	—
Other adjustment		—	—			—	—			—	—			—	—			—	—
Non-GAAP adjusted gross profit	$	32,134	42.9	%	$	34,088	46.5	%	$	40,097	49.8	%	$	36,259	47.9	%	$	142,578	46.8	%

	Multiomics
	Quarter Ended																Year Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
Dollars in thousands	2022				2022				2022				2021				2022
GAAP gross profit	$	26,523	42.3	%	$	25,890	43.6	%	$	31,123	47.9	%	$	31,115	48.7	%	$	114,650	45.7	%
Adjustments:
Amortization of completed technology		1,373	2.2			1,433	2.4			1,445	2.2			1,443	2.3			5,693	2.3
Tariff adjustment		2	—			—	—			(486)	(0.7)			—	—			(484)	(0.2)
Other adjustment		289	0.5			—	—			—	—			—	—			289	0.1
Non-GAAP adjusted gross profit	$	28,187	45.0	%	$	27,322	46.0	%	$	32,081	49.4	%	$	32,558	51.0	%	$	120,148	47.9	%

	B Medical Systems
	Quarter Ended																Year Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
Dollars in thousands	2022				2022				2022				2021				2022
GAAP gross profit	$	—	—	%	$	—	—	%	$	—	—	%	$	—	—	%	$	—	—	%
Adjustments:
Amortization of completed technology		—	—			—	—			—	—			—	—			—	—
Tariff adjustment		—	—			—	—			—	—			—	—			—	—
Other adjustment		—	—			—	—			—	—			—	—			—	—
Non-GAAP adjusted gross profit	$	—	—	%	$	—	—	%	$	—	—	%	$	—	—	%	$	—	—	%

	Azenta Total
	Quarter Ended																Year Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
Dollars in thousands	2022				2022				2022				2021				2022
GAAP gross profit	$	58,129	42.3	%	$	59,600	44.9	%	$	70,825	48.7	%	$	67,044	48.0	%	$	255,597	46.0	%
Adjustments:
Amortization of completed technology		1,901	1.4			1,812	1.4			1,840	1.3			1,773	1.3			7,324	1.3
Tariff adjustment		2	0.0			—	—			(486)	(0.3)			—	—			(484)	(0.1)
Other adjustment		289	0.2			—	—			—	—			—	—			289	0.1
Non-GAAP adjusted gross profit	$	60,321	43.8	%	$	61,412	46.3	%	$	72,179	49.6	%	$	68,817	49.3	%	$	262,726	47.3	%

Reconciliation of GAAP to Non-GAAP Operating (Loss) Profit – Fiscal 2023


	Sample Management Solutions
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2023		2023		2023		2022		2023
GAAP operating (loss) profit	$	4,992	$	70	$	(7,221)	$	(3,476)	$	(5,633)
Adjustments:
Amortization of completed technology		867		744		933		429		2,973
Purchase accounting impact on inventory		—		—		—		—		—
Amortization of other intangibles		51		(1)		212		48		311
Other Adjustment		—		—		—		—		—
Non-GAAP adjusted operating profit (loss)	$	5,910	$	813	$	(6,076)	$	(2,998)	$	(2,349)

	Multiomics
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2023		2023		2023		2022		2023
GAAP operating (loss) profit	$	(4,502)	$	(4,632)	$	(5,037)	$	(4,481)	$	(18,652)
Adjustments:
Amortization of completed technology		1,211		1,220		1,226		1,215		4,874
Purchase accounting impact on inventory		—		—		—		—		—
Amortization of other intangibles		—		—		—		—		—
Other Adjustment		—		—		—		—		—
Non-GAAP adjusted operating profit (loss)	$	(3,291)	$	(3,412)	$	(3,810)	$	(3,265)	$	(13,779)

	B Medical Systems
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2023		2023		2023		2022		2023
GAAP operating (loss) profit	$	(7,153)	$	(4,129)	$	(9,021)	$	(454)	$	(20,757)
Adjustments:
Amortization of completed technology		2,691		2,692		2,742		2,523		10,647
Purchase accounting impact on inventory		927		2,956		2,912		2,869		9,664
Amortization of other intangibles		—		1		—		1,365		1,366
Other Adjustment		(1)		—		—		—		(1)
Non-GAAP adjusted operating profit (loss)	$	(3,537)	$	1,520	$	(3,367)	$	6,303	$	919

	Corporate
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2023		2023		2023		2022		2023
GAAP operating (loss) profit	$	(9,964)	$	(7,145)	$	8,302	$	(19,274)	$	(28,083)
Adjustments:
Amortization of other intangibles		7,430		7,522		7,297		5,959		28,207
Restructuring Charges		804		812		1,499		1,462		4,577
Rebranding and transformation costs		(15)		21		10		(65)		(49)
Contingent consideration adjustment		—		(1,404)		(17,145)		—		(18,549)
Merger and acquisition costs & costs related to share repurchase		1,767		219		19		11,838		13,842
Other Adjustment		—		(2)		—		—		—
Non-GAAP adjusted operating profit (loss)	$	22	$	23	$	(18)	$	(80)	$	(55)

	Azenta Total
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2023		2023		2023		2022		2023
GAAP operating (loss) profit	$	(16,628)	$	(15,836)	$	(12,977)	$	(27,684)	$	(73,126)
Adjustments:
Amortization of completed technology		4,769		4,656		4,901		4,168		18,494
Purchase accounting impact on inventory		927		2,956		2,912		2,869		9,664
Amortization of other intangibles		7,481		7,522		7,509		7,372		29,884
Restructuring Charges		804		812		1,499		1,462		4,577
Rebranding and transformation costs		(15)		21		10		(65)		(49)
Contingent consideration adjustment		—		(1,404)		(17,145)		—		(18,549)
Merger and acquisition costs & costs related to share repurchase		1,767		219		19		11,838		13,842
Other Adjustment		(1)		(2)		—		—		(1)
Non-GAAP adjusted operating profit (loss)	$	(896)	$	(1,056)	$	(13,272)	$	(40)	$	(15,264)

Reconciliation of GAAP to Non-GAAP Operating (Loss) Profit – Fiscal 2022


	Sample Management Solutions
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2022		2022		2022		2021		2022
GAAP operating (loss) profit	$	2,513	$	5,402	$	7,805	$	6,613	$	22,335
Adjustments:
Amortization of completed technology		528		379		395		330		1,631
Tariff adjustment		—		—		—		—		—
Amortization of other intangibles		—		—		5		—		5
Other Adjustment		(1)		—		—		—		—
Non-GAAP adjusted operating profit (loss)	$	3,041	$	5,781	$	8,205	$	6,943	$	23,970

	Multiomics
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2022		2022		2022		2021		2022
GAAP operating (loss) profit	$	(2,642)	$	(2,749)	$	985	$	3,888	$	(518)
Adjustments:
Amortization of completed technology		1,373		1,434		1,445		1,443		5,693
Tariff adjustment		2		—		(486)		—		(484)
Amortization of other intangibles		339		—		(5)		—		340
Other Adjustment		(1)		—		—		—		—
Non-GAAP adjusted operating profit (loss)	$	(930)	$	(1,315)	$	1,939	$	5,331	$	5,032

	B Medical Systems
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2022		2022		2022		2021		2022
GAAP operating (loss) profit	$	—	$	—	$	—	$	—	$	—
Adjustments:
Amortization of completed technology		—		—		—		—		—
Tariff adjustment		—		—		—		—		—
Amortization of other intangibles		—		—		—		—		—
Other Adjustment		—		—		—		—		—
Non-GAAP adjusted operating profit (loss)	$	—	$	—	$	—	$	—	$	—

	Corporate
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2022		2022		2022		2021		2022
GAAP operating (loss) profit	$	(14,490)	$	(7,726)	$	(13,499)	$	(10,826)	$	(46,552)
Adjustments:
Amortization of other intangibles		6,561		5,745		6,047		6,272		24,620
Restructuring Charges		393		25		122		173		712
Rebranding and transformation costs		536		289		1,297		619		2,741
Contingent consideration adjustment		—		—		600		—		600
Merger and acquisition costs & costs related to share repurchase		6,959		1,662		4,989		3,719		17,329
Other Adjustment		—		—		—		—		—
Non-GAAP adjusted operating profit (loss)	$	(41)	$	(5)	$	(444)	$	(43)	$	(550)

	Azenta Total
	Quarter Ended								Year Ended
	September 30,		June 30,		March 31,		December 31,		September 30,
Dollars in thousands	2022		2022		2022		2021		2022
GAAP operating (loss) profit	$	(14,619)	$	(5,073)	$	(4,708)	$	(325)	$	(24,735)
Adjustments:
Amortization of completed technology		1,901		1,813		1,840		1,773		7,324
Amortization of other intangibles		6,900		5,745		6,047		6,272		24,965
Tariff adjustment		2		—		(486)		—		(484)
Restructuring Charges		393		25		122		173		712
Rebranding and transformation costs		536		289		1,297		619		2,741
Contingent consideration adjustment		—		—		600		—		600
Merger and acquisition costs & costs related to share repurchase		6,959		1,662		4,989		3,719		17,329
Other Adjustment		(2)		—		—		—		—
Non-GAAP adjusted operating profit (loss)	$	2,070	$	4,461	$	9,701	$	12,231	$	28,452

Organic Revenue – Fiscal 2023


	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Quarter Ended						Quarter Ended						Quarter Ended						Quarter Ended
	September 30,		September 30,				September 30,		September 30,				September 30,		September 30,				September 30,		September 30,
Dollars in millions	2023		2022		Change		2023		2022		Change		2023		2022		Change		2023		2022		Change
Revenue	$	82	$	75	9	%	$	61	$	63	(2)	%	$	29	$	—	—	%	$	172	$	138	25	%
Acquisitions/divestitures		1		—	(1)	%		—		—	—	%		29		—	—	%		30		—	(22)	%
Currency exchange rates		2		—	(3)	%		(0)		—	0	%		—		—	—	%		2		—	(1)	%
Organic revenue	$	79	$	75	5	%	$	61	$	63	(2)	%	$	—	$	—	—	%	$	140	$	138	2	%

	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Quarter Ended						Quarter Ended						Quarter Ended						Quarter Ended
	June 30,		June 30,				June 30,		June 30,				June 30,		June 30,				June 30,		June 30,
Dollars in millions	2023		2022		Change		2023		2022		Change		2023		2022		Change		2023		2022		Change
Revenue	$	75	$	73	3	%	$	64	$	59	8	%	$	27	$	—	—	%	$	166	$	133	25	%
Acquisitions/divestitures		5		—	(7)	%		—		—	—	%		27		—	—	%		32		—	(24)	%
Currency exchange rates		(0)		—	0	%		(1)		—	1	%		—		—	—	%		(1)		—	0	%
Organic revenue	$	70	$	73	(4)	%	$	64	$	59	8	%	$	—	$	—	—	%	$	135	$	133	2	%

	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Quarter Ended						Quarter Ended						Quarter Ended						Quarter Ended
	March 31,		March 31,				March 31,		March 31,				March 31,		March 31,				March 31,		March 31,
Dollars in millions	2023		2022		Change		2023		2022		Change		2023		2022		Change		2023		2022		Change
Revenue	$	71	$	81	(12)	%	$	62	$	65	(4)	%	$	15	$	—	—	%	$	148	$	146	2	%
Acquisitions/divestitures		4		—	(5)	%		—		—	—	%		15		—	—	%		19		—	(13)	%
Currency exchange rates		(2)		—	3	%		(2)		—	3	%		—		—	—	%		(4)		—	3	%
Organic revenue	$	70	$	81	(14)	%	$	64	$	65	(1)	%	$	—	$	—	—	%	$	134	$	146	(8)	%

	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Quarter Ended						Quarter Ended						Quarter Ended						Quarter Ended
	December 31,		December 31,				December 31,		December 31,				December 31,		December 31,				December 31,		December 31,
Dollars in millions	2022		2021		Change		2022		2021		Change		2022		2021		Change		2022		2021		Change
Revenue	$	75	$	76	(0)	%	$	61	$	64	(4)	%	$	42	$	—	—	%	$	178	$	140	28	%
Acquisitions/divestitures		4		—	(5)	%		—		—	—	%		42		—	—	%		46		—	(33)	%
Currency exchange rates		(3)		—	4	%		(3)		—	5	%		—		—	—	%		(6)		—	4	%
Organic revenue	$	75	$	76	(1)	%	$	64	$	64	0	%	$	—	$	—	—	%	$	139	$	140	(1)	%

	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Year Ended						Year Ended						Year Ended						Year Ended
	September 30,		September 30,				September 30,		September 30,				September 30,		September 30,				September 30,		September 30,
Dollars in millions	2023		2022		Change		2023		2022		Change		2023		2022		Change		2023		2022		Change
Revenue	$	304	$	305	(0)	%	$	248	$	251	(1)	%	$	113	$	—	—	%	$	665	$	555	20	%
Acquisitions/divestitures		14		—	(4)	%		—		—	—	%		113		—	—	%		127		—	(23)	%
Currency exchange rates		(4)		—	1	%		(6)		—	2	%		—		—	—	%		(9)		—	2	%
Organic revenue	$	294	$	305	(4)	%	$	254	$	251	1	%	$	—	$	—	—	%	$	547	$	555	(1)	%

Organic Revenue – Fiscal 2022


	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Quarter Ended						Quarter Ended						Quarter Ended						Quarter Ended
	September 30,		September 30,				September 30,		September 30,				September 30,		September 30,				September 30,		September 30,
Dollars in millions	2022		2021		Change		2022		2021		Change		2022		2021		Change		2022		2021		Change
Revenue	$	75	$	78	(3)	%	$	63	$	59	6	%	$	—	$	—	—	%	$	138	$	137	0	%
Acquisitions/divestitures		4		—	(5)	%		—		—	—	%		—		—	—	%		4		—	(3)	%
Currency exchange rates		(4)		—	5	%		(2)		—	4	%		—		—	—	%		(6)		—	4	%
Organic revenue	$	75	$	78	(4)	%	$	65	$	59	9	%	$	—	$	—	—	%	$	139	$	137	2	%

	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Quarter Ended						Quarter Ended						Quarter Ended						Quarter Ended
	June 30,		June 30,				June 30,		June 30,				June 30,		June 30,				June 30,		June 30,
Dollars in millions	2022		2021		Change		2022		2021		Change		2022		2021		Change		2022		2021		Change
Revenue	$	73	$	70	4	%	$	59	$	59	1	%	$	—	$	—	—	%	$	133	$	129	3	%
Acquisitions/divestitures		—		—	—	%		—		—	—	%		—		—	—	%		—		—	—	%
Currency exchange rates		(2)		—	4	%		(1)		—	2	%		—		—	—	%		(4)		—	3	%
Organic revenue	$	76	$	70	8	%	$	61	$	59	3	%	$	—	$	—	—	%	$	137	$	129	6	%

	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Quarter Ended						Quarter Ended						Quarter Ended						Quarter Ended
	March 31,		March 31,				March 31,		March 31,				March 31,		March 31,				March 31,		March 31,
Dollars in millions	2022		2021		Change		2022		2021		Change		2022		2021		Change		2022		2021		Change
Revenue	$	81	$	73	11	%	$	65	$	57	15	%	$	—	$	—	—	%	$	146	$	130	12	%
Acquisitions/divestitures		2		—	(2)	%		—		—	—	%		—		—	—	%		2		—	(1)	%
Currency exchange rates		(1)		—	1	%		(1)		—	1	%		—		—	—	%		(2)		—	1	%
Organic revenue	$	80	$	73	10	%	$	66	$	57	16	%	$	—	$	—	—	%	$	145	$	130	12	%

	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Quarter Ended						Quarter Ended						Quarter Ended						Quarter Ended
	December 31,		December 31,				December 31,		December 31,				December 31,		December 31,				December 31,		December 31,
Dollars in millions	2021		2020		Change		2021		2020		Change		2021		2020		Change		2021		2020		Change
Revenue	$	76	$	68	12	%	$	64	$	50	27	%	$	—	$	—	—	%	$	140	$	118	18	%
Acquisitions/divestitures		2		—	(3)	%		—		—	—	%		—		—	—	%		2		—	(2)	%
Currency exchange rates		0		—	(1)	%		0		—	(0)	%		—		—	—	%		0		—	(0)	%
Organic revenue	$	73	$	68	8	%	$	64	$	50	27	%	$	—	$	—	—	%	$	137	$	118	16	%

	Sample Management Solutions						Multiomics						B Medical Systems						Azenta Total
	Year Ended						Year Ended						Year Ended						Year Ended
	September 30,		September 30,				September 30,		September 30,				September 30,		September 30,				September 30,		September 30,
Dollars in millions	2022		2021		Change		2022		2021		Change		2022		2021		Change		2022		2021		Change
Revenue	$	305	$	289	6	%	$	251	$	225	11	%	$	—	$	—	—	%	$	555	$	514	8	%
Acquisitions/divestitures		8		—	(3)	%		—		—	—	%		—		—	—	%		8		—	(2)	%
Currency exchange rates		(7)		—	2	%		(4)		—	2	%		—		—	—	%		(11)		—	2	%
Organic revenue	$	303	$	289	5	%	$	255	$	225	13	%	$	—	$	—	—	%	$	558	$	514	9	%

Document and Entity Information	Jan. 31, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Jan. 31, 2024
Entity Registrant Name	Azenta, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	0-25434
Entity Tax Identification Number	04-3040660
Entity Address, Address Line One	200 Summit Drive
Entity Address, City or Town	Burlington
Entity Address State Or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	978
Local Phone Number	262-2400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	AZTA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0000933974
Amendment Flag	false